Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Abboud CN, Altman J et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 10(8), 984–1021 (2012).
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13), 4372–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358(18), 1909–1918 (2008).
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12), 4326–4335 (2002).
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12(9), 1333–1337 (1998).
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11(10), 1605–1609 (1997).
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10(12), 1911–1918 (1996).
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5), 1532–1542 (2002).
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Towatari M, Kiyoi H et al. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19(5), 624–631 (2000).
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H et al. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96(12), 3907–3914 (2000).
   PubMed Web of Science ®Google Scholar
• Choudhary C, Brandts C, Schwable J et al. Activation mechanisms of STAT5 by oncogenic FLT3-ITD. Blood 110(1), 370–374 (2007).
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3(9), 650–665 (2003).
   PubMed Web of Science ®Google Scholar
• Choudhary C, Muller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic FLT3. Int. J. Hematol. 82(2), 93–99 (2005).
   PubMed Web of Science ®Google Scholar
• Bagrintseva K, Schwab R, Kohl TM et al. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 103(6), 2266–2275 (2004).
   Google Scholar
• Lee BH, Tothova Z, Levine RL et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 12(4), 367–380 (2007).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98(6), 1752–1759 (2001).
   PubMed Web of Science ®Google Scholar
• Whitman SP, Archer KJ, Feng L et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 61(19), 7233–7239 (2001).
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93(9), 3074–3080 (1999).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8), 2434–2439 (2001).
   PubMed Web of Science ®Google Scholar
• Bienz M, Ludwig M, Leibundgut EO et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin. Cancer Res. 11(4), 1416–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Santos FP, Jones D, Qiao W et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 117(10), 2145–2155 (2011).
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 111(5), 2527–2537 (2008).
   PubMed Web of Science ®Google Scholar
• Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4), 1262–1270 (2007).
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19(8), 1345–1349 (2005).
   PubMed Web of Science ®Google Scholar
• Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk. Res. 28(6), 547–550 (2004).
   Google Scholar
• Kayser S, Schlenk RF, Londono MC et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114(12), 2386–2392 (2009).
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Kottaridis PD et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106(10), 3658–3665 (2005).
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Arceci RJ, Sanders JE et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 108(1), 400; author reply 400–401 (2006).
   Google Scholar
• Brunet S, Labopin M, Esteve J et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J. Clin. Oncol. 30(7), 735–741 (2012).
   PubMed Web of Science ®Google Scholar
• Sengsayadeth SM, Jagasia M, Engelhardt BG et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 47(12), 1535–1537 (2012).
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Illmer T, Schaich M et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 109(5), 2264–2265; author reply 2265 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshimoto G, Nagafuji K, Miyamoto T et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 36(11), 977–983 (2005).
   Google Scholar
• Palmieri S, Ferrara F, Leoni F et al. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol. Oncol. 25(1), 1–5 (2007).
   Google Scholar
• Dezern AE, Sung A, Kim S et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol. Blood Marrow Transplant. 17(9), 1404–1409 (2011).
   PubMed Web of Science ®Google Scholar
• Singh H, Werner LL, Asali S et al. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am. J. Hematol. 86(7), 625–627 (2011).
   Google Scholar
• De Labarthe A, Pautas C, Thomas X et al. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. Bone Marrow Transplant. 35(8), 767–773 (2005).
   Google Scholar
• Ustun C, Lazarus HM, Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. doi:10.1038/bmt.2013.67 (2013) [ Epub ahead of print].
   Google Scholar
• Imahashi N, Suzuki R, Fukuda T et al. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplant. 48(1), 56–62 (2013).
   Google Scholar
• Kayser S, Dohner K, Krauter J et al. Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications. In:ASH Annual Meeting Blood 909 (2010).
   Google Scholar
• Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8(5), 935–942 (2002).
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 36(11), 1009–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer 117(15), 3293–3304 (2011).
   PubMed Web of Science ®Google Scholar
• Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115(7), 1425–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Auclair D, Miller D, Yatsula V et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21(3), 439–445 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi YX et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J. Natl Cancer Inst. 100(3), 184–198 (2008).
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104(4), 1145–1150 (2004).
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11(15), 5472–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Andreef M et al. Phase I trial of intermittent administration of sorafenib (BAY 43–9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML). In: ASCO Annual Meeting J. Clin. Oncol. 378–390 (2007).
   Google Scholar
• Pratz KW, Cho E, Karp J et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. In: 2009 ASCO Annual Meeting: J. Clin. Oncol. 27(15S), 7065 (2009).
   Google Scholar
• Borthakur G, Kantarjian H, Ravandi F et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1), 62–68 (2011).
   PubMed Web of Science ®Google Scholar
• Safaian NN, Czibere A, Bruns I et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk. Res. 33(2), 348–350 (2009).
   Google Scholar
• Martinez-Lopez J, Castro N, Rueda D, Canal A, Grande C, Ayala R. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. Br. J. Haematol. 158(4), 555–558 (2012).
   Google Scholar
• Ravandi F, Cortes JE, Jones D et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J. Clin. Oncol. 28(11), 1856–1862 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Kali A, Cortes J, Faderl S et al. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 11(4), 361–366 (2011).
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23), 4655–4662 (2013).
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J. Clin. Oncol. 31(25), 3110–3118 (2013).
   PubMed Web of Science ®Google Scholar
• Wolleschak D, Schalk E, Krogel C et al. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. J. Hematol. Oncol. 6, 39 (2013).
   Google Scholar
• Sharma M, Ravandi F, Bayraktar UD et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol. Blood Marrow Transplant. 17(12), 1874–1877 (2011).
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113(26), 6567–6571 (2009).
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Lundqvist A, Su S, Childs R. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 116(15), 2858–2859 (2010).
   Google Scholar
• Metzelder SK, Schroeder T, Finck A et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 26(11), 2353–2359 (2012).
   PubMed Web of Science ®Google Scholar
• Kruger WH, Hirt C, Kiefer T, Neumann T, Busemann C, Dolken G. Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib. Bone Marrow Transplant. 47(1), 137–138 (2012).
   Google Scholar
• Knapper S, Mills KI, Gilkes AF, Austin SJ, Walsh V, Burnett AK. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108(10), 3494–3503 (2006).
   Google Scholar
• Smith BD, Levis M, Beran M et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10), 3669–3676 (2004).
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108(10), 3262–3270 (2006).
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117(12), 3294–3301 (2011).
   PubMed Web of Science ®Google Scholar
• O’farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9), 3597–3605 (2003).
   Google Scholar
• Yee KW, Schittenhelm M, O’farrell AM et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104(13), 4202–4209 (2004).
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3), 986–993 (2005).
   PubMed Web of Science ®Google Scholar
• O’farrell AM, Foran JM, Fiedler W et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9(15), 5465–5476 (2003).
   PubMed Web of Science ®Google Scholar
• Propper DJ, Mcdonald AC, Man A et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19(5), 1485–1492 (2001).
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 26(9), 2061–2068 (2012).
   PubMed Web of Science ®Google Scholar
• Stone RM, Deangelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105(1), 54–60 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol. 28(28), 4339–4345 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Paz K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs 11(1), 46–56 (2008).
   PubMedGoogle Scholar
• Deangelo DJ, Stone RM, Heaney ML et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108(12), 3674–3681 (2006).
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 8(16), 2621–2630 (2009).
   PubMed Web of Science ®Google Scholar
• Shiotsu Y, Kiyoi H, Ishikawa Y et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 114(8), 1607–1617 (2009).
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cortes J, Roboz GJ et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113(17), 3938–3946 (2009).
   PubMed Web of Science ®Google Scholar
• Zarrinkar PP, Gunawardane RN, Cramer MD et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114(14), 2984–2992 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes J, A P, C S et al. AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: Interim results. 16th Congress of the European Hematology Association, London, UK, 9–12 June 2011 ( Abstract 1019).
   Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24), 5089–5102 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 120(19), 4049–4057 (2012).
   PubMed Web of Science ®Google Scholar
• Cortes J, Foran J, Ghirdaladze D et al. AC220, A potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human phase 1 AML study. ASH Annual Meeting Abstracts. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Wang ES, Yee K, Koh LP et al. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk. Lymphoma 53(8), 1543–1551 (2012).
   PubMed Web of Science ®Google Scholar
• Fathi AT, Arowojolu O, Swinnen I et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk. Res. 36(2), 224–231 (2012).
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118(3), 693–702 (2011).
   PubMed Web of Science ®Google Scholar
• Hospital MA, Green AS, Lacombe C, Mayeux P, Bouscary D, Tamburini J. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood 119(7), 1791–1792 (2012).
   Google Scholar
• Gozgit JM, Wong MJ, Wardwell S et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10(6), 1028–1035 (2011).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Roesel J, Furet P et al. Antileukemic effects of novel first- and second-generation FLT3 inhibitors: structure-affinity comparison. Genes Cancer 1(10), 1021–1032 (2010).
   Google Scholar
• Ahmad R, Liu S, Weisberg E et al. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol. Cancer Res. 8(7), 986–993 (2010).
   Google Scholar
• Lin WH, Jiaang WT, Chen CW et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br. J. Cancer 106(3), 475–481 (2012).
   Google Scholar
• Burkholder TP, Clayton JR, Rempala ME et al. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Invest. New Drugs 30(3), 936–949 (2012).
   Google Scholar
• Heidary DK, Huang G, Boucher D et al. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J. Med. Chem. 55(2), 725–734 (2012).
   Google Scholar
• Goh KC, Novotny-Diermayr V, Hart S et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 26(2), 236–243 (2012).
   PubMed Web of Science ®Google Scholar
• Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br. J. Haematol. 159(2), 191–203 (2012).
   PubMed Web of Science ®Google Scholar
• Pasha MK, Jayaraman R, Reddy VP et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab. Lett. 6(1), 33–42 (2012).
   Google Scholar
• Davies RJ, Pierce AC, Forster C et al. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia. J. Med. Chem. 54(20), 7184–7192 (2011).
   Google Scholar
• Nordigarden A, Zetterblad J, Trinks C et al. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice. Br. J. Haematol. 155(2), 198–208 (2011).
   Google Scholar
• Williams AB, Nguyen B, Li L et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 27(1), 48–55 (2013).
   PubMed Web of Science ®Google Scholar
• Cao ZX, Liu JJ, Zheng RL et al. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia 26(8), 1892–1895 (2012).
   PubMed Web of Science ®Google Scholar
• Man CH, Fung TK, Ho C et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 119(22), 5133–5143 (2012).
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Kantarjian HM, Ravandi F et al. FLT3 inhibitor treatment in FLT3-mutated AML is associated with development of secondary FLT3-TKD mutations. ASH Annual Meeting. San Diego, CA, USA, 10 December 2011.
   Google Scholar
• Smith CC, Wang Q, Chin CS et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397), 260–263 (2012).
   PubMed Web of Science ®Google Scholar
• Heidel F, Solem FK, Breitenbuecher F et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107(1), 293–300 (2006).
   PubMed Web of Science ®Google Scholar
• Bagrintseva K, Geisenhof S, Kern R et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 105(9), 3679–3685 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Jacamo RO et al. Acquired point mutations of TKD are responsible for sorafenib resistance in FLT3-ITD mutant AML. ASH Annual Meeting 118(21) (2011).
   Google Scholar
• Mohi MG, Boulton C, Gu TL et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl Acad. Sci. USA 101(9), 3130–3135 (2004).
   Google Scholar
• Hernandez-Davies JE, Zape JP, Landaw EM et al. The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3beta-dependent pathway. Mol. Cancer Ther. 10(6), 949–959 (2011).
   Google Scholar
• Ikezoe T, Nishioka C, Tasaka T et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol. Cancer Ther. 5(10), 2522–2530 (2006).
   Google Scholar
• Zhou J, Bi C, Chng WJ et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PloS ONE 6(5), e19798 (2011).
   PubMed Web of Science ®Google Scholar
• Neubauer A, Fiebeler A, Graham DK et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84(6), 1931–1941 (1994).
   PubMed Web of Science ®Google Scholar
• Hong CC, Lay JD, Huang JS et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268(2), 314–324 (2008).
   PubMed Web of Science ®Google Scholar
• Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 121(11), 2064–2073 (2013).
   PubMed Web of Science ®Google Scholar
• Reddy PN, Sargin B, Choudhary C et al. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood 120(8), 1691–1702 (2012).
   Google Scholar